(NP (NP (NN Lymphocyte) (NN glucocorticoid) (NN receptor) (NN binding)) (PP-TMP-COOD (PP (IN during) (NP (NN depression))) (CC and) (PP (IN after) (NP (JJ clinical) (NN recovery)))) (. .))
(S (NP-SBJ-58 (NN Lymphocyte) (NN glucocorticoid) (NN receptor) (NN binding) (NNS parameters)) (VP (VBD were) (VP-COOD (VP (VBN studied) (NP (-NONE- *-58)) (PP-106 (IN in) (NP (CD 15) (ADJP (RB severely) (JJ depressed)) (NNS patients))) (PP-TMP-COOD (PP (IN during) (NP (NN depression))) (CC and) (PP (IN after) (NP (JJ clinical) (NN recovery))))) (, ,) (CC and) (VP (PP=106 (IN in) (NP (CD 15) (JJ healthy) (NNS controls)))))) (. .))
(S (NP-SBJ (EX There)) (VP (VBD was) (NP-PRD (NP (DT no) (NN difference)) (PP (IN in) (NP (NN glucocorticoid) (NN receptor) (NP-COOD (NP (NN number)) (CC or) (NP (NN affinity))))) (PP (IN between) (NP-COOD (NP (JJ depressed) (NNS patients)) (CC and) (NP (ADJP-COOD (ADJP (JJ recovered)) (CC or) (ADJP (NN control))) (NNS subjects)))))) (. .))
(S (NP-SBJ (NN Afternoon) (NP-COOD (NP (NN ACTH)) (CC and) (NP (NN cortisol))) (NNS concentrations)) (VP (VBD did) (RB not) (VP (VB differ) (ADVP (RB significantly)) (PP (IN between) (NP (DT the) (CD three) (NNS groups))))) (. .))
(S (NP-SBJ-59 (DT No) (NN relationship)) (VP (MD could) (VP (VB be) (VP (VBN established) (NP (-NONE- *-59)) (PP (IN between) (NP-COOD (NP (NN glucocorticoid) (NN receptor) (NN binding)) (CC and) (NP (JJ antidepressant) (NN medication))))))) (. .))
(S (NP-SBJ (DT These) (NNS data)) (VP (VBP support) (NP-COOD (NP (NP (DT the) (NN view)) (PP (IN of) (NP (NP (DT an) (ADJP (JJ impaired) (JJ ligand-induced)) (NN plasticity)) (PP (IN of) (NP (NN glucocorticoid) (NN receptor) (NN regulation)))))) (CONJP (RB rather) (IN than)) (NP (NP (DT the) (NN hypothesis)) (PP (IN of) (NP (NP (VBN decreased) (NN glucocorticoid) (NN receptor) (NNS numbers)) (PP-TMP (IN during) (NP (NN depression)))))))) (. .))
